Michael L Schulte1,2,3, Matthew R Hight2, Gregory D Ayers4, Qi Liu5, Yu Shyr5,6, M Kay Washington6,7, H Charles Manning8,9,10,11,12,13,14,15. 1. Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 2. Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 3. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 4. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 5. Vanderbilt Center for Quantitative Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 6. Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 7. Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. 8. Vanderbilt Center for Molecular Probes, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu. 9. Vanderbilt University Institute of Imaging Science (VUIIS), Vanderbilt University Medical Center, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu. 10. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu. 11. Vanderbilt-Ingram Cancer Center (VICC), Vanderbilt University Medical Center, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu. 12. Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu. 13. Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu. 14. Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu. 15. Department of Chemistry, Vanderbilt University, Nashville, TN, 37232, USA. henry.c.manning@vanderbilt.edu.
Abstract
PURPOSE: This study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake may reflect critical processes in oncology. Approximately, 10 % of patients with colorectal cancer (CRC) express BRAF V600E , which may be actionable with selective BRAF inhibitors or in combination with inhibitors of complementary signaling axes. Non-invasive and quantitative predictive measures of response to these targeted therapies remain poorly developed in this setting. The primary objective of this study was to explore 4-[18F]fluoroglutamine (4-[18F]F-GLN) positron emission tomography (PET) to predict response to BRAFV600E-targeted therapy in preclinical models of colon cancer. PROCEDURES: Tumor microarrays from patients with primary human colon cancers (n = 115) and CRC liver metastases (n = 111) were used to evaluate the prevalence of ASCT2, the primary glutamine transporter in oncology, by immunohistochemistry. Subsequently, 4-[18F]F-GLN PET was evaluated in mouse models of human BRAF V600E -expressing and BRAF wild-type CRC. RESULTS: Approximately 70 % of primary colon cancers and 53 % of metastases exhibited positive ASCT2 immunoreactivity, suggesting that [18F]4-F-GLN PET could be applicable to a majority of patients with colon cancer. ASCT2 expression was not associated selectively with the expression of mutant BRAF. Decreased 4-[18F]F-GLN predicted pharmacological response to single-agent BRAF and combination BRAF and PI3K/mTOR inhibition in BRAF V600E -mutant Colo-205 tumors. In contrast, a similar decrease was not observed in BRAF wild-type HCT-116 tumors, a setting where BRAFV600E-targeted therapies are ineffective. CONCLUSIONS: 4-[18F]F-GLN PET selectively reflected pharmacodynamic response to BRAF inhibition when compared with 2-deoxy-2[18F]fluoro-D-glucose PET, which was decreased non-specifically for all treated cohorts, regardless of downstream pathway inhibition. These findings illustrate the utility of non-invasive PET imaging measures of glutamine uptake to selectively predict response to BRAF-targeted therapy in colon cancer and may suggest further opportunities to inform colon cancer clinical trials using targeted therapies against MAPK activation.
PURPOSE: This study aimed to study whether cancer cells possess distinguishing metabolic features compared with surrounding normal cells, such as increased glutamine uptake. Given this, quantitative measures of glutamine uptake may reflect critical processes in oncology. Approximately, 10 % of patients with colorectal cancer (CRC) express BRAFV600E , which may be actionable with selective BRAF inhibitors or in combination with inhibitors of complementary signaling axes. Non-invasive and quantitative predictive measures of response to these targeted therapies remain poorly developed in this setting. The primary objective of this study was to explore 4-[18F]fluoroglutamine (4-[18F]F-GLN) positron emission tomography (PET) to predict response to BRAFV600E-targeted therapy in preclinical models of colon cancer. PROCEDURES: Tumor microarrays from patients with primary humancolon cancers (n = 115) and CRC liver metastases (n = 111) were used to evaluate the prevalence of ASCT2, the primary glutamine transporter in oncology, by immunohistochemistry. Subsequently, 4-[18F]F-GLN PET was evaluated in mouse models of humanBRAFV600E -expressing and BRAF wild-type CRC. RESULTS: Approximately 70 % of primary colon cancers and 53 % of metastases exhibited positive ASCT2 immunoreactivity, suggesting that [18F]4-F-GLN PET could be applicable to a majority of patients with colon cancer. ASCT2 expression was not associated selectively with the expression of mutant BRAF. Decreased 4-[18F]F-GLN predicted pharmacological response to single-agent BRAF and combination BRAF and PI3K/mTOR inhibition in BRAFV600E -mutant Colo-205 tumors. In contrast, a similar decrease was not observed in BRAF wild-type HCT-116tumors, a setting where BRAFV600E-targeted therapies are ineffective. CONCLUSIONS:4-[18F]F-GLN PET selectively reflected pharmacodynamic response to BRAF inhibition when compared with 2-deoxy-2[18F]fluoro-D-glucose PET, which was decreased non-specifically for all treated cohorts, regardless of downstream pathway inhibition. These findings illustrate the utility of non-invasive PET imaging measures of glutamine uptake to selectively predict response to BRAF-targeted therapy in colon cancer and may suggest further opportunities to inform colon cancer clinical trials using targeted therapies against MAPK activation.
Authors: David R Wise; Ralph J DeBerardinis; Anthony Mancuso; Nabil Sayed; Xiao-Yong Zhang; Harla K Pfeiffer; Ilana Nissim; Evgueni Daikhin; Marc Yudkoff; Steven B McMahon; Craig B Thompson Journal: Proc Natl Acad Sci U S A Date: 2008-11-24 Impact factor: 11.205
Authors: Eliot T McKinley; Joseph E Bugaj; Ping Zhao; Saffet Guleryuz; Christine Mantis; Prafulla C Gokhale; Robert Wild; H Charles Manning Journal: Clin Cancer Res Date: 2011-01-21 Impact factor: 12.531
Authors: Barbara J Fueger; Johannes Czernin; Isabel Hildebrandt; Chris Tran; Benjamin S Halpern; David Stout; Michael E Phelps; Wolfgang A Weber Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Brian P Lieberman; Karl Ploessl; Limin Wang; Wenchao Qu; Zhihao Zha; David R Wise; Lewis A Chodosh; George Belka; Craig B Thompson; Hank F Kung Journal: J Nucl Med Date: 2011-11-15 Impact factor: 10.057
Authors: Matt I Gross; Susan D Demo; Jennifer B Dennison; Lijing Chen; Tania Chernov-Rogan; Bindu Goyal; Julie R Janes; Guy J Laidig; Evan R Lewis; Jim Li; Andrew L Mackinnon; Francesco Parlati; Mirna L M Rodriguez; Peter J Shwonek; Eric B Sjogren; Timothy F Stanton; Taotao Wang; Jinfu Yang; Frances Zhao; Mark K Bennett Journal: Mol Cancer Ther Date: 2014-02-12 Impact factor: 6.261
Authors: Qian Wang; Rae-Anne Hardie; Andrew J Hoy; Michelle van Geldermalsen; Dadi Gao; Ladan Fazli; Martin C Sadowski; Seher Balaban; Mark Schreuder; Rajini Nagarajah; Justin J-L Wong; Cynthia Metierre; Natalia Pinello; Nicholas J Otte; Melanie L Lehman; Martin Gleave; Colleen C Nelson; Charles G Bailey; William Ritchie; John E J Rasko; Jeff Holst Journal: J Pathol Date: 2015-04-07 Impact factor: 7.996
Authors: Allison S Cohen; Joe Grudzinski; Gary T Smith; Todd E Peterson; Jennifer G Whisenant; Tiffany L Hickman; Kristen K Ciombor; Dana Cardin; Cathy Eng; Laura W Goff; Satya Das; Robert J Coffey; Jordan D Berlin; H Charles Manning Journal: J Nucl Med Date: 2021-04-30 Impact factor: 11.082
Authors: Michael L Schulte; Allie Fu; Ping Zhao; Jun Li; Ling Geng; Shannon T Smith; Jumpei Kondo; Robert J Coffey; Marc O Johnson; Jeffrey C Rathmell; Joe T Sharick; Melissa C Skala; Jarrod A Smith; Jordan Berlin; M Kay Washington; Michael L Nickels; H Charles Manning Journal: Nat Med Date: 2018-01-15 Impact factor: 53.440